Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MAFB shapes human monocyte-derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression

  • Simón-Fuentes, Miriam
  • Ríos, Israel
  • Herrero, Cristina
  • Lasala, Fátima
  • Labiod, Nuria
  • Luczkowiak, Joanna
  • Roy-Vallejo, Emilia
  • Fernández de Córdoba-Oñate, Sara
  • Delgado-Wicke, Pablo
  • Bustos, Matilde
  • Fernández-Ruiz, Elena
  • Colmenares, María
  • Puig-Kröger, Amaya
  • Delgado, Rafael
  • Vega Palacios, Miguel A.
  • Corbí, Angel L.
  • Domínguez-Soto, Ángeles
22 p.-6 fig.1 graph. abst., Monocyte-derived macrophages, the major source of pathogenic macrophages in COVID-19, are oppositely instructed by macrophage CSF (M-CSF) or granulocyte macrophage CSF (GM-CSF), which promote the generation of antiinflammatory/immunosuppressive MAFB+ (M-MØ) or proinflammatory macrophages (GM-MØ), respectively. The transcriptional profile of prevailing macrophage subsets in severe COVID-19 led us to hypothesize that MAFB shapes the transcriptome of pulmonary macrophages driving severe COVID-19 pathogenesis. We have now assessed the role of MAFB in the response of monocyte-derived macrophages to SARS-CoV-2 through genetic and pharmacological approaches, and we demonstrate that MAFB regulated the expression of the genes that define pulmonary pathogenic macrophages in severe COVID-19. Indeed, SARS-CoV-2 potentiated the expression of MAFB and MAFB-regulated genes in M-MØ and GM-MØ, where MAFB upregulated the expression of profibrotic and neutrophil-attracting factors. Thus, MAFB determines the transcriptome and functions of the monocyte-derived macrophage subsets that underlie pulmonary pathogenesis in severe COVID-19 and controls the expression of potentially useful biomarkers for COVID-19 severity., This work was supported by grant PID2020-114323RB-I00 from Ministerio de Ciencia e Innovación to ALC; “Ayudas FUNDACIÓN BBVA a equipos de investigación científica SARS-CoV-2 y COVID-19” to MAV and ALC; Dirección General de Innovación e Investigación Tecnológica de la Comunidad de Madrid (RETARACOVID, P2022/BMD-7274) to ALC, APK, EFR, and RD; Instituto de Salud Carlos III (grant PI20/00316 to APK, grant PI2100989 to RD, grant PI22/00428 to EFR); Red de Enfermedades Inflamatorias (RICORS RD21/0002/0034) from Instituto de Salud Carlos III and cofinanced by the European Regional Development Fund “A way to achieve Europe” (ERDF) and PRTR to APK; European Commission Horizon 2020 FP (Project VIRUSCAN FETPROACT-2016: ID 731868); Horizon Europe FP (Project EPIC-CROWN-2 ID: 101046084); and Fundación Caixa-Health Research (Project StopEbola HR18-00469) to RD. This research was also funded by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). MSF was funded by a Formación de Personal Investigador predoctoral fellowship from Ministerio de Ciencia e Innovación (grant PRE2018-083396). ERV was funded by a Rio-Hortega grant CM19/00149 from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) and cofunded by the ERDF. SFDCO was funded by the PREDINMUN-COVID Grant (Fondo Supera COVID-19 from Banco de Santander and CRUE) and PDW by PI19/00096., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses

  • Pérez Ramírez, Patricia
  • Astorgano, David
  • Albericio, Guillermo
  • Flores, Sara
  • Sánchez-Corzo, Cristina
  • Noriega, María A.
  • Sánchez-Cordón, Pedro J.
  • Labiod, Nuria
  • Delgado, Rafael
  • Casasnovas, José María
  • Esteban, Mariano
  • García-Arriaza, Juan
Despite the decrease in mortality and morbidity due to SARS-CoV-2 infection, the incidence of infections due to Omicron subvariants of SARS-CoV-2 remains high. The mutations acquired by these subvariants, mainly concentrated in the receptor-binding domain (RBD), have caused a shift in infectivity and transmissibility, leading to a loss of effectiveness of the first authorized COVID-19 vaccines, among other reasons, by neutralizing antibody evasion. Hence, the generation of new vaccine candidates adapted to Omicron subvariants is of special interest in an effort to overcome this immune evasion. Here, an optimized COVID-19 vaccine candidate, termed MVA-S(3P_BA.1), was developed using a modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein from the Omicron BA.1 variant. The immunogenicity and efficacy induced by MVA-S(3P_BA.1) were evaluated in mice in a head-to-head comparison with the previously generated vaccine candidates MVA-S(3P) and MVA-S(3Pbeta), which express prefusion-stabilized S proteins from Wuhan strain and Beta variant, respectively, and with a bivalent vaccine candidate composed of a combination of MVA-S(3P) and MVA-S(3P_BA.1). The results showed that all four vaccine candidates elicited, after a single intramuscular dose, protection of transgenic K18-hACE2 mice challenged with SARS-CoV-2 Omicron BA.1, reducing viral loads, histopathological lesions, and levels of proinflammatory cytokines in the lungs. They also elicited anti-S IgG and neutralizing antibodies against various Omicron subvariants, with MVA-S(3P_BA.1) and the bivalent vaccine candidate inducing higher titers. Additionally, an intranasal immunization in C57BL/6 mice with all four vaccine candidates induced systemic and mucosal S-specific CD4+ and CD8+ T-cell and humoral immune responses, and the bivalent vaccine candidate induced broader immune responses, eliciting antibodies against the ancestral Wuhan strain and different Omicron subvariants. These results highlight the use of MVA as a potent and adaptable vaccine vector against new emerging SARS-CoV-2 variants, as well as the promising feature of combining multivalent MVA vaccine candidates., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by Fondo COVID-19 grant COV20/00151 (Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)), Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander), CSIC grant 202120E079, grant CNS2022-135511 funded by the Spanish Ministry of Science, Innovation and Universities (MCIU)/Spanish Research Agency (AEI)/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR to promote the consolidation of research, and funds from Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to JG-A); CSIC grant 2020E84, la Caixa Banking Foundation grant CF01-00008, Ferrovial, and MAPFRE donations (to ME); and Spanish MCIU/AEI/10.13039/501100011033 grant PID2020-114481RB-I00 (to JG-A and ME). This research work was also funded by the European Commission-NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). JG-A also received grants from the European Commission HORIZON-HLTH-2023-DISEASE-03-18 (Project MARVAX: 101137183 and Project FLAVIVACCINE: 101137006). JG-A and ME also acknowledges financial support from the Spanish AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). JC acknowledges MCIU and CSIC support (project number 202020E079). RD received grants from ISCIII (FIS PI2100989), the European Commission Horizon 2020 Framework Programme (Project VIRUSCAN FETPROACT-2016: 731868 and Project EPIC-CROWN-2: 101046084), and Fundación Caixa-Health Research HR18-00469 (Project StopEbola). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

Superior neutralizing response after first versus second SARS‐CoV‐2 infection in fully vaccinated individuals

  • Rivas Hernández, Gonzalo
  • Labiod Becerro, Nuria
  • Luczkowiak, Joanna
  • Lasala Sánchez, Fátima
  • Rolo, Marta
  • Mancheño Losa, Mikel
  • Rial Crestelo, David
  • Lora-Tamayo Morillo-Velarde, Jaime
  • Pérez Rivilla, José Alfredo
  • Folgueira López, María Dolores
  • Delgado Vázquez, Rafael
Currently, the majority of the population has been vaccinated against COVID‐19and/or has experienced SARS‐CoV‐2 infection either before or after vaccination.The immunological response to repeated episodes of infections is not completelyclear. We measured SARS‐CoV‐2 specific neutralization titers by a pseudovirusassay after BA.1 infection and RBD‐specific immunoglobulin G (IgG), immuno-globulin A (IgA), and immunoglobulin M (IgM) in a cohort of COVID‐19uninfected and triple vaccinated individuals (breakthrough infection group,BTI) as compared with those previously infected by SARS‐CoV‐2 (reinfectiongroup, REI) who underwent identical vaccination schedule. SARS‐CoV‐2specificneutralizing response after BA.1 infection was significantly higher in the BTIgroup as compared with the REI. Furthermore, neutralization titers in REI werenot significant different from convalescent non reinfected controls. RBD‐specific IgG and IgA, but not IgM, werealso significantly higher in BTI ascompared with REI. Our results show that the first episode of SARS‐CoV‐2infection induces a significant increase inneutralizing titers in triple vaccinatedindividuals and that previous SARS‐CoV‐2 infection compromise significantly theneutralization response induced by reinfection, even by divergent SARS‐CoV‐2variants and at least up to 2 years postinfection, suggesting a fundamentallimitation in inducing effective booster through the intranasal route in previouslyinfected individuals